Saad F - Search Results

1

Intra-individual comparison of ¹⁸F-sodium fluoride PET-CT and ^99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial.

Bénard F, Harsini S, Wilson D, Zukotynski K, Abikhzer G, Turcotte E, Cossette M, Metser U, Romsa J, Martin M, Mar C, Saad F, Soucy JP, Eigl BJ, Black P, Krauze A, Burrell S, Nichol A, Tardif JC. Bénard F, et al. Among authors: saad f. Lancet Oncol. 2022 Dec;23(12):1499-1507. doi: 10.1016/S1470-2045(22)00642-8. Epub 2022 Nov 4. Lancet Oncol. 2022. PMID: 36343655 Clinical Trial.

2

Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.

Saad F. Saad F. Semin Oncol. 2002 Dec;29(6 Suppl 21):19-27. doi: 10.1053/sonc.2002.37418. Semin Oncol. 2002. PMID: 12584691 Review.

3

Validation of 1997 Partin Tables' lymph node invasion predictions in men treated with radical prostatectomy in Montreal Quebec.

Karakiewicz PI, Lattouf JB, Perrotte P, Valiquette L, Bénard F, McCormack M, Ménard C, Lebeau T, Benayoun S, Ramirez A, Ouaknine S, Saad F. Karakiewicz PI, et al. Among authors: saad f. Can J Urol. 2005 Apr;12(2):2588-92. Can J Urol. 2005. PMID: 15877940

4

Bone health in men with prostate cancer: diagnostic and therapeutic considerations.

Saad F, Perrotte P, Bénard F, McCormack M, Karakiewicz PI. Saad F, et al. Can J Urol. 2005 Jun;12 Suppl 2:9-15. Can J Urol. 2005. PMID: 16018826 Review.

5

Validation of prostate cancer index and SF-12 short forms.

Lebeau T, Perrotte P, Valiquette L, Bénard F, McCormack M, Saad F, Karakiewicz PI. Lebeau T, et al. Among authors: saad f. Can J Urol. 2005 Dec;12(6):2873-9. Can J Urol. 2005. PMID: 16401372

6

Prostate cancer nomograms are superior to neural networks.

Karakiewicz PI, Chun FK, Briganti A, Perrotte P, McCormack M, Bénard F, Valiquette L, Graefen M, Saad F. Karakiewicz PI, et al. Among authors: saad f. Can J Urol. 2006 Apr;13 Suppl 2:18-25. Can J Urol. 2006. PMID: 16672124 Review.

7

Therapeutic approach to hormone-refractory prostate cancer.

Saad F, Al Dejmah A, Perrotte P, McCormack M, Bénard F, Valiquette L, Karakiewicz PI. Saad F, et al. Can J Urol. 2006 Apr;13 Suppl 2:52-6. Can J Urol. 2006. PMID: 16672130 Review.

8

Bone-directed treatments for prostate cancer.

Saad F. Saad F. Hematol Oncol Clin North Am. 2006 Aug;20(4):947-63. doi: 10.1016/j.hoc.2006.03.011. Hematol Oncol Clin North Am. 2006. PMID: 16861125 Review.

9

Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening.

Hutterer G, Perrotte P, Gallina A, Walz J, Jeldres C, Traumann M, Suardi N, Saad F, Bénard F, Valiquette L, McCormack M, Graefen M, Montorsi F, Karakiewicz PI. Hutterer G, et al. Among authors: saad f. Eur J Cancer. 2007 May;43(7):1180-7. doi: 10.1016/j.ejca.2007.01.005. Epub 2007 Feb 9. Eur J Cancer. 2007. PMID: 17292604

10

Chronic inflammation is negatively associated with prostate cancer and high-grade prostatic intraepithelial neoplasia on needle biopsy.

Karakiewicz PI, Benayoun S, Bégin LR, Duclos A, Valiquette L, McCormack M, Bénard F, Saad F, Perrotte P. Karakiewicz PI, et al. Among authors: saad f. Int J Clin Pract. 2007 Mar;61(3):425-30. doi: 10.1111/j.1742-1241.2006.00905.x. Int J Clin Pract. 2007. PMID: 17313610

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,415 results

Search Page

Filters